Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 0.54 |
| ▸ | PDE4A | P27815 | 9/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.54 |
| ▸ | PDE5A | O76074 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021952 | 0.91 | PDE4A (0.64) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL20021950 | 0.87 | SLC6A3 (0.50) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL20021945 | 0.87 | PDE4A (0.60) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL23685091 | 0.81 | CYP11B1 (0.56) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| SCHEMBL20021948 | 0.81 | PDE4A (0.63) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL35823 | 0.81 | PTGS2 (0.58) | PTGS2EGFRALDH1A1SMN1; SMN2 | |
| SCHEMBL20021951 | 0.80 | PDE4B (0.54) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7364684 | 0.80 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL5309884 | 0.80 | PDE4D (0.67) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL20021956 | 0.79 | CNR1 (0.53) | PDE4DPDE4APDE4BPDE4CPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | PDE4D 3631/4885PDE4A 4232/4885PDE4B 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.